Bone Marrow-Derived NCS-01 Cells Advance a Novel Cell-Based Therapy for Stroke

Area of Science:

• Neuroscience
• Regenerative Medicine
• Stem Cell Biology

Background:

• Human mesenchymal stem cells (MSCs) are investigated for cell-based stroke therapies.
• Critical steps for clinical translation include identifying safe, effective cell lines and optimizing delivery parameters.
• Preclinical data is essential for advancing MSCs towards human stroke trials.

Purpose of the Study:

• To review preclinical advancements of NCS-01 cells for ischemic stroke treatment.
• To evaluate the efficacy and safety of NCS-01 cells in in vitro and in vivo stroke models.
• To provide a framework for initiating human clinical trials based on preclinical findings.

Main Methods:

• In vitro studies involving coculturing NCS-01 cells with primary rat cortical cells and human neural progenitor cells under oxygen-glucose deprivation.
• In vivo studies using the rodent middle cerebral artery occlusion (MCAO) model.
• Intracarotid artery administration of NCS-01 cells and assessment of functional recovery, infarct volume, and cell loss.

Main Results:

• NCS-01 cells conferred functional recovery in ischemic stroke models.
• Coculturing with NCS-01 cells protected neural cells against oxygen-glucose deprivation.
• Intracarotid administration of NCS-01 cells showed superior efficacy compared to other MSCs in improving motor and neurological function, reducing infarct volume, and minimizing cell loss.

Conclusions:

• NCS-01 cells demonstrate therapeutic potential for ischemic stroke through functional recovery and neuroprotection.
• The cells secrete therapeutic factors and may employ novel mechanisms like filopodia extension towards injury sites.
• Preclinical evidence supports NCS-01 cell transplantation for human stroke trials, aligning with STEPS recommendations.